Skip to main content
. 2016 Nov 23;80(6):909–923. doi: 10.1002/ana.24815

Figure 8.

Figure 8

Delayed treatment with phosphodiesterase 4 (PDE4) inhibitors improves motor function in Cln3Δex7/8 mice. Cln3Δex7/8 and wild‐type (WT) mice (n = 8/group) received vehicle, (A, C) 5mg/kg roflumilast (RF), or (B, D) 0.5mg/kg PF‐06266047 (PF) via daily oral gavage beginning at 3 months of age, after which motor activity was assessed by accelerating rotarod testing at monthly intervals. Across all comparisons, significant differences between vehicle‐treated WT and Cln3Δex7/8 animals are denoted by asterisks, Cln3Δex7/8 vehicle‐treated versus Cln3Δex7/8 PDE4 inhibitor‐treated mice are indicated by hash signs, and WT vehicle‐treated versus WT PDE4 inhibitor‐treated mice are indicated by ampersand signs. (C, D) Weights of Cln3Δex7/8 and WT mice receiving delayed PDE4 inhibitor treatment. Significant differences between Cln3Δex7/8 vehicle‐treated versus Cln3Δex7/8 PDE4 inhibitor‐treated mice are indicated by hash signs, and WT vehicle‐treated versus WT PDE4 inhibitor‐treated mice are indicated by ampersand signs. For all comparisons, *, #, & reflect p < 0.05; **, ##, && denote p < 0.01; ###, &&& reflect p < 0.001; and ****, ####, &&&& represent p < 0.0001.